Visus Therapeutics is a clinical-stage company in pursuit of developing the the world's first presbyopia-correcting eye drop with the potential to last at least eight hours.
With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Media contact: firstname.lastname@example.org
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. Our pipeline of early-stage ophthalmic product candidates includes applications in ocular surface disease, glaucoma, and age-related macular degeneration.
View our August 31st Capital Markets Day Presentation here.
November 30, 2021
November 3, 2021
September 14, 2021
September 30, 2021
September 22, 2021
September 1, 2021